What if the key to ADC efficacy lies not in the target, but in the cell’s trafficking machinery?
In recent publication by Medhus co-authored by founders of Rab Diagnostics Anette Weyergang, Olav Engebraaten and Kristian Berg, the study shows that the mechanisms of HER2-targeted ADCs T-DM1 and T-DXd depend heavily on Rab GTPase-regulated trafficking, not just HER2 expression.
Key Findings:
T-DM1 efficacy strongly correlates with HER2 + RAB5A expression.
T-DXd efficacy depends primarily on RAB5A, independent of HER2 levels.
Linker design dictates whether payload release requires full lysosomal trafficking (T-DM1) or occurs earlier (T-DXd).
Bystander killing is crucial for T-DXd effectiveness in HER2-low settings.
Impact:
✅ Intracellular trafficking pathways should be studied during development of ADCs
✅ RAB5A emerges as a predictive biomarker for the efficacy of two different HER2-targeted ADCs.
✅ Tailoring ADC design to trafficking mechanism could enhance clinical outcomes.
Read the article here:
https://journals.sagepub.com/doi/epub/10.1177/17588359251332473